CompletedPhase 2NCT03679767
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Studying Acquired cystic disease-associated renal cell carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Incyte Corporation
- Principal Investigator
- Mark Cornfeld, MDIncyte Corporation
- Intervention
- Retifanlimab(drug)
- Enrollment
- 121 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2022
Study locations (30)
- California Cancer Associates for Research and Excellence, Inc., Fresno, California, United States
- California Cancer Associates for Research and Excellence, Fresno, California, United States
- California Cancer Associates for Research and Excellence, Inc., San Marcos, California, United States
- St Joseph Heritage Healthcare, Santa Rosa, California, United States
- St. Joseph Health Medical Group - Annadel Medical Group, Santa Rosa, California, United States
- Rocky Mountain Cancer Centers - Denver - Midtown, Denver, Colorado, United States
- Christiana Care Helen F. Graham Cancer Center, Newark, Delaware, United States
- Rcca Md, Llc, Bethesda, Maryland, United States
- VA New Jersey Health Care System, East Orange, New Jersey, United States
- New York Oncology Hematology - Albany, Albany, New York, United States
- Kaiser Permanente, Portland, Oregon, United States
- Texas Oncology Surgical Specialists - Austin Central, Austin, Texas, United States
- Coastal Bend Cancer Center, Corpus Christi, Texas, United States
- AIM Trials, LLC, Plano, Texas, United States
- Texas Oncology - San Antonio Northeast, San Antonio, Texas, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03679767 on ClinicalTrials.govOther trials for Acquired cystic disease-associated renal cell carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06882486Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic TherapyInstitut Paoli-Calmettes
- RECRUITINGPHASE1NCT07517198Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid TumorsExscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- RECRUITINGNANCT06907095Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk IndividualsGustave Roussy, Cancer Campus, Grand Paris
- RECRUITINGNANCT07461090Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost AnalysisMenoufia University
- RECRUITINGNANCT07402109CBCT Guided Markerless SBRT for Renal Cell CancerErasmus Medical Center
- RECRUITINGPHASE1NCT07195682A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)Bristol-Myers Squibb
- RECRUITINGPHASE1NCT07006688A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal ImpairmentServier Bio-Innovation LLC
- RECRUITINGPHASE1, PHASE2NCT07219576Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego
See all trials for Acquired cystic disease-associated renal cell carcinoma →